M1-20

M1-20 is a CDK1 inhibitor. M1-20 promotes CDK1 ubiquitination by CUL4-DDB1-DCAF1 complexes and degradation through the proteasome pathway. M1-20 abolishes the formation of CDK1/CCNB1 complexes. M1-20 has significant anticancer activity of spontaneous breast cancer in FVB/N MMTV-PyVT mice model[1].

Product Specifications

UNSPSC

12352209

Target

CDK

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

O=C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(N[C@H](CCC(N)=O)C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCCN)C(N[C@H](CCCCN)C(N[C@H](CCCNC(N)=N)C(N[C@H](CC(C)C)C(NCC(N1[C@H](CCC1)C(N[C@H](CC2=CC=CC=C2)C(N[C@H](CO)C(N[C@H]([C@H](C)CC)C(N[C@H](CC(O)=O)C(N[C@H](CC(C)C)C(N[C@H](CC(C)C)C(N[C@H]([C@H](C)CC)C(N[C@H](CCCCN)C(N[C@H](CO)C(N[C@H](CC(C)C)C(N[C@H](CO)C(N[C@H](CC(O)=O)C(N[C@H](CC(N)=O)C(N[C@H](CCSC)C(N[C@H]([C@@H](O)C)C(N[C@H](CC(O)=O)C(N[C@H](CC(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CN

Molecular Formula

C153H269N53O43S

Molecular Weight

3571.17

References & Citations

[1]Bu H, et al. The antitumor peptide M1-20 induced the degradation of CDK1 through CUL4-DDB1-DCAF1-involved ubiquitination. Cancer Gene Ther. 2025 Jan;32 (1) :61-70.